Transvaginal ultrasound measurement of endometrial thickness as a biomarker for estrogen exposure

Graduate School of Public Health, Magee-Women's Hospital, University of Pittsburgh, Pennsylvania, USA.
Cancer Epidemiology Biomarkers & Prevention (Impact Factor: 4.13). 10/2004; 13(9):1459-65.
Source: PubMed


In clinical settings, transvaginal ultrasound has been used to evaluate abnormal vaginal bleeding. Because the endometrium responds to estrogens, endometrial thickness may constitute a biomarker of estrogen status in postmenopausal women. This study aimed to validate the transvaginal ultrasonographic measurement of endometrial thickness as an estrogen biomarker in asymptomatic, postmenopausal women by demonstrating an association between endometrial thickness and risk factors known to be associated with estrogen exposure.
Endometrial thickness was measured in 1,271 women ages 55 to 74 years who underwent transvaginal ultrasound screening as part of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. A questionnaire, completed before screening, provided risk factor information, including reproductive and hormone use histories.
Endometrial thickness measurements ranged from 1 to 32 mm (median 3.0 mm). The frequencies of thicker endometrium (> or =3.0 mm), according to body mass index (BMI) quartile, were 55.2%, 66.1%, 69.7%, and 76.7% (P < 0.0001). The frequencies of thicker endometrium were 57.8%, 58.3%, and 82.6% among never users, ex-users, and current users of hormone replacement therapy (HRT), respectively (P < 0.0001). Other factors associated with thicker endometrium included age, marital status, history of uterine fibroids, years since menopause, and history of hypertension. Statistically significant associations were not seen in analyses limited to current HRT users (n = 461). In multiple variable analysis (R2 = 0.08), current HRT use (P < 0.0001) and higher BMI (P < 0.0001) were independently associated with thicker endometrium.
In postmenopausal women, factors reflecting exogenous (current HRT use) and endogenous (BMI) estrogen exposure were associated with increased endometrial thickness as measured during screening transvaginal ultrasound. Practical limitations related to screening transvaginal ultrasound include measurement variability, lack of information regarding type or dose of HRT, and problems of differentiating true endometrial thickening from unrecognized endometrial polyps or fluid accumulations. Constrained by these limitations, these results partially validate a transvaginal ultrasound measurement of endometrial thickness as a potential biomarker related to estrogen status.

1 Follower
18 Reads
    • "We, however, observed no significant effects of leptin on pre-embryonic development as the rate of fertilization and production of good-quality embryos did not differ between the low and high serum and FF leptin groups. Reports[27] indicate that endometrial thickness bears positive correlation with follicular phase serum estradiol concentration. In order to rule out any masking effects of estradiol on leptin-associated endometrial thickness, we isolated three categories of patients who had peak estradiol level between 1800 and 2500 pg/mL and exhibited varied leptin responses: high, moderate, and low between post-hCG and OPU day. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A critical body mass of adipose tissue is essential for the normal development of female reproductive functions. Leptin, an adipocyte-derived hormone encoded by the 'Ob' gene has been proposed as a peripheral signal indicating the adequacy of nutritional status for reproductive functions. It is reported as a direct regulator of gametogenic and steroidogenic potential of ovary. Though leptin is widely present in reproductive tissues, its relationship to reproductive hormones is still poorly understood. Present investigation attempts to explore ovarian response to secretory profile of leptin and its impact on pregnancy outcome in women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer (IVF-ET). Patients enrolled for IVF-ET underwent pituitary-ovarian suppression by 'Long Protocol' GnRH-agonist downregulation followed by ovarian stimulation. Sera were procured at different phases of IVF-ET for the assay of estradiol, progesterone, human chorionic gonadotropin, and for leptin. Ovarian follicular fluids were also assayed for leptin. Luteinized granulosa cells were cultured in vitro to evaluate their steroidogenic potential. Statistical analyses were done by student's t-test, ANOVA, and Chi-square tests as applicable. All results were expressed as Mean ┬▒ SE. P values < 0.05 were considered significant. Positive correlation was observed between serum and ovarian follicular fluid leptin. A negative correlation was noted between the serum leptin levels and endometrial thickness. Elevated leptin response may exert adverse impacts on pregnancy success during IVF-ET possibly by modulating uterine receptivity.
    05/2012; 5(2):194-9. DOI:10.4103/0974-1208.101021
  • Source
    • "[12] "
    [Show abstract] [Hide abstract]
    ABSTRACT: To verify the relationship between clinical variables and tumor stage in breast cancer. This retrospective study (1998 to 2001) analyzed data of 176 women with breast cancer attending a university hospital. Patients were divided into groups according to the clinicopathological variables studied. The disease had a similar frequency at age under 50 years (44.3%) or above (55.7%) 50 years. Stage II was more frequent. Most patients were white (69.9%), non-smokers (69.3%) and were not using oral contraceptives (71%). Stages 0-II were mainly detected in the white (74.8%) vs non-white (60.4%) group. Monthly breast self-exams were performed by 62.5% of women, in which earlier stages (0, I) were more frequently detected than in those who did not perform self-exams (27.3% vs 12.1%, p = 0.01). Breast cancer occurred mainly in white women in Stage II, and with similar frequency at age under or over 50 years. Breast self-exam was associated with early detection of the disease.
    European journal of gynaecological oncology 02/2008; 29(1):80-2. · 0.61 Impact Factor
  • Source
    • "[12] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Malignancies are one of the major causes of morbidity and mortality in transplant patients. The incidence is progressively increasing either because of the increased age transplant patients and the increase of immunosuppressive therapy or the increased follow-up range post-transplantation. The main causes of increased tumor incidence in transplant patients with respect to the general population are the reduced immunosurveillance and the high incidence of infections due to oncogenic viruses. This problem might become more and more serious in the near future due to the introduction of new immunosuppressive strategies that significantly extend allograft survival. A case of ovarian cancer in a kidney transplant patient is described. Attention is focused on the potential dual role of immunosuppressive therapy in the development of malignancies in transplant patients.
    European journal of gynaecological oncology 02/2008; 29(1):89-92. · 0.61 Impact Factor
Show more